Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c
August 9, 2022 7:17 AM EDTFoghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.66), $0.09 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $8.69 million.
For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.
... More